Search Results
Your search for The ASCO ,The ASCO matches 21461 pages
Showing 19301 - 19350In Memoriam: John Michael Fitzpatrick, MCh, FRSCI
John Michael Fitzpatrick, MCh, FRSCI, was one of Europe’s most highly regarded medical opinion leaders. He studied medicine at University College Dublin and did his clinical internship at St. Vincent’s Hospital in Dublin. While doing his residency at St. Vincent’s, he decided to become a urologist, ...
In Memoriam: Eddie Reed, MD
Eddie Reed, MD, was a pioneer in the molecular pharmacology of DNA-damaging anticancer agents and the clinical development of paclitaxel for ovarian cancer. He graduated from Yale University School of Medicine in 1979, completed his internship and residency at Stanford University in 1981, and was...
A Tribute to James F. Holland, MD, in Celebration of His 90th Birthday
Far and away the best prize that life has to offer is the chance to work hard at work worth doing. —Theodore Roosevelt Longevity, in and of itself, is not an accomplishment. Luck and good genes are just human lottery tickets. Most people fortunate enough to live long lives have a productive sweet ...
2015 Oncology Meetings
JUNE 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review 2015: Highlights of the Annual MeetingJune 19 • New Haven, Connecticut For more information:...
After a Long and Distinguished Career, Robert C. Young, MD, Shows No Sign of Slowing Down
Robert C. Young, MD, ASCO Past President, longtime leader of Fox Chase Cancer Center, and an internationally recognized expert in lymphoma and ovarian cancer, is a forward-looking doctor who is confident about something not in his future: retirement. “I’ll never quit working; I’m just not wired...
Andrew C. von Eschenbach, MD, Went From the Front Lines of Cancer Care to a Bird’s-Eye View of the Changing Oncology Landscape
At the end of the day, I’m still a kid from South Philly,” Andrew C. von Eschenbach, MD, former Director of the National Cancer Institute (NCI) and Commissioner of the U.S. Food and Drug Administration (FDA), told The ASCO Post. Dr. von Eschenbach is the product of a closely knit yet culturally...
Nationally Recognized Leader in Myeloid Malignancies, Alan F. List, MD, Has High Hopes for the Future of Oncology
The Tampa Bay area of Florida is a haven for golfers and fishermen looking to unwind under the warm tropical skies. And the clean highways stretching through the scenic west coast of Florida are also a perfect excuse for weekend motorcycle enthusiasts, such as Alan F. List, MD, the President and...
Lymphoma Expert and Industry Leader Sandra J. Horning, MD, Pushes the Frontiers of Drug Development and Oncology Research
Due to childhood health issues, Sandra J. Horning, MD, formed an opinion about doctors at a young age: They were good people who helped other people. By her early teens, Dr. Horning began to ponder a career in medicine, which offered the possibility of blending her love of science with a career...
‘Father of Geriatric Oncology’ Lodovico Balducci, MD, Unearthed a New Understanding of Aging’s Effect on Cancer Treatment
At the 2007 ASCO Annual Meeting, Lodovico Balducci, MD, received the inaugural B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology. Called the “patriarch of geriatric oncology,” Dr. Balducci is widely known in the oncology community for his warm humor and thick Italian...
ASCO Announces First-Ever Clinical Trial
ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and Drug...
Expect Questions About Preventing Fractures After Stem Cell Transplant
Does the finding that the incidence of fractures is “compellingly higher” after hematopoietic stem cell transplantation mean that physicians counseling patients about transplant should feel compelled to discuss the fracture risks? Huifang Linda Lu, MD, PhD, the corresponding author of the study...
Incidence of Fractures Is ‘Compellingly Higher’ After Hematopoietic Stem Cell Transplantation
The incidence of fractures is “compellingly higher” after receiving hematopoietic stem cell transplantation, according to a retrospective study of patients receiving transplants for treatment of multiple myeloma, other hematologic malignancies, and some solid tumors (mostly breast and ovarian) as...
Gerstner Family Foundation Commits $10 Million to Broad Institute
Broad Institute of MIT and Harvard announced a $10 million gift from the Gerstner Family Foundation, which will expand cancer research at Broad Institute and broaden collaborations with Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center. The research will focus on the...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Margaret Foti Recognized as 2015 Honoree of the ‘One Hundred’ by Massachusetts General Hospital Cancer Center
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), was honored for her “dedication and commitment to solving cancer through research” and for her “passionate advocacy for increased federal funding for cancer research and biomedical science,” at Massachusetts...
Meir Wetzler, MD, RPCI Leukemia Chief, Dies at Age 60
Meir Wetzler, MD, Chief of the Leukemia Section at Roswell Park Cancer Institute and University at Buffalo (UB) Professor of Medicine, died on February 23 from injuries sustained during a skiing accident in Colorado. He was 60 years old. Nationally prominent in his field, Dr. Wetzler helped set...
Carol A. Kruse, PhD, Pioneer in Brain Cancer Research and Immunotherapy, Dies at Age 61
Carol A. Kruse, PhD, a University of California, Los Angeles (UCLA) scientist and recognized leader in immunologic therapy for brain cancer, recently passed away in Los Angeles after a 6-month battle with an aggressive form of cancer. She was 61. Dr. Kruse was a UCLA Professor of Neurosurgery and...
Alan C. Sartorelli, PhD, Pioneer in Targeted Chemotherapy and AACR Past President, Dies at Age 83
Alan C. Sartorelli, PhD, Alfred Gilman Professor of Pharmacology at Yale University School of Medicine, Past President of the American Association for Cancer Research (AACR), and a Fellow of the AACR Academy, died on April 30, 2015. A pioneer in cancer chemotherapy, Dr. Sartorelli was one of the...
2015 Oncology Meetings
JUNE The International Society of Ocular Oncology (ISOO) MeetingJune 16-19 • Paris, France For more information: http://www.isoo.org 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review...
Martin McMahon, PhD, Joins Research Team at Huntsman Cancer Institute
Martin McMahon, PhD, will join Huntsman Cancer Institute (HCI) at the University of Utah in August 2015 as Professor in the Department of Dermatology and HCI Senior Director of Preclinical Translation. Dr. McMahon is currently the Efim Guzik Distinguished Professor of Cancer Biology at the...
Jonathan L. Finlay, MB, ChB, FRCP, Recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer
During the Wyss Family Symposium, hosted by Nationwide Children’s Hospital May 11–12, Jonathan L. Finlay, MB, ChB, FRCP, Director of Neuro-Oncology at Nationwide Children’s, was announced as the first recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer. Dr. Finlay is...
Mount Sinai Receives $8.8 Million Grant to Further Stem Cell Research
An $8.8 million grant from the New York State Stem Cell Science Program (NYSTEM) will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders. Increasing Stem Cells...
How and When to Give Professional Feedback
Providing students and residents with feedback on their medical performance is a key element in their learning and development and ensures that high standards are met, according to Charlene M. Dewey, MD, MEd, FACP, Assistant Dean of Educator Development; Associate Professor of Medical Education and ...
Five Oncology Researchers Selected as Howard Hughes Medical Institute Investigators
The Howard Hughes Medical Institute announced 26 of the nation’s top biomedical researchers as investigators for the Institute. These scientists will receive the flexible support necessary to move their research in creative new directions. The initiative represents an investment in basic biomedical ...
Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?
The phase III RAISE trial—reported by Tabernero and colleagues in The Lancet Oncology1 and reviewed in this issue of The ASCO Post—demonstrated that ramucirumab (Cyramza), a fully human IgG1 monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR2) extracellular domain, in...
Nancy Brinker Named May LUNGevity Hero
The LUNGevity Foundation has announced Nancy Brinker, Founder and Chief of Global Strategy of Susan G. Komen, as the May LUNGevity Hero in recognition of her decades-long dedication and trailblazing work in the fight against cancer. A true pioneer of the advocacy movement, Ms. Brinker gave a...
Daniel D. Von Hoff, MD, FACP, Receives the 2015 Wallace A. Reed, MD, Award
Daniel D. Von Hoff, MD, FACP, Distinguished Professor and Physician-in-Chief of the Translational Genomics Research Institute (TGen), received the 2015 Wallace A. Reed, MD, Award on May 29 from the Arizona Medical Association (ArMA). The award recognizes his accomplishments in advancing innovative...
Roswell Park Cancer Institute Appoints New Leadership Team
Roswell Park Cancer Institute recently announced a restructuring of its leadership. “In many cases, these new appointments represent Roswell Park Cancer Institute parlaying our own existing strengths and talents,” says President and CEO Candace Johnson, PhD. “Restructuring some of these positions...
ASCO 2015—Investigators Announce Patient Enrollment for NCI-MATCH Trial
Investigators for the nationwide trial, NCI-MATCH: Molecular Analysis for Therapy Choice (EAY131), have announced that the precision medicine trial will open to patient enrollment in July. The announcement was made recently during ASCO’s Annual Meeting in Chicago. The MATCH trial seeks to determine ...
Fulfilling NCI’s Commitment to Supporting the Best Science
On April 1, 2015, Douglas R. Lowy, MD, became Acting Director of the National Cancer Institute (NCI), succeeding Harold Varmus, MD, who left NCI to join the faculty of Weill Cornell Medical College in New York. (See “The Next Step in a Storied Career,” in the May 25, 2015 issue of The ASCO Post.)...
ASCO Appoints Lidia Schapira, MD, FASCO, Editor in Chief of Patient Information Website, Cancer.Net
ASCO appointed Lidia Schapira, MD, FASCO, a medical oncologist at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, the new Editor in Chief of its award-winning patient information website, Cancer.Net. Dr. Schapira assumed this role at the...
The Promise of Immune Checkpoint Inhibition: Changing the Therapeutic Landscape for Melanoma and Other Malignancies
The past 3 years have witnessed transformative changes in the way that solid tumors and hematologic malignancies are approached, in almost every instance now including consideration of some form of immunomodulation in the first- or later-line therapeutic setting. The greatest success has occurred...
Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman
Kenneth C. Frazier, JD, Chairman and CEO of Merck & Co., Inc., was elected Chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Frazier formerly held the position of Chairman-Elect and succeeds Ian C. Read, Chairman and CEO of Pfizer, Inc. New Officers ...
New ASCO University® Tumor Genomics Program Helps Cancer Care Providers Increase Their Understanding of Next-Generation Sequencing
Innovation in the field of genomic assessment and characterization has rapidly progressed in recent years. As next-generation sequencing increasingly becomes a standard of care, it is vital for cancer care providers to develop a deeper understanding of its research and clinical applications. For...
ASCO’s Community Research Forum Offers Helpful Tools for Community-Based Research Sites
As part of ASCO’s efforts to support research sites and clinical investigators, ASCO’s Community Research Forum (CRF) was created as a solution-oriented venue for community-based research sites. The Forum and its working groups have developed several tools and resources that aim to help researchers ...
Over 30 Organizations, Including ASCO, Call for FDA to Regulate E-Cigarettes
ASCO, together with 30 organizations, have sent a letter to President Obama asking for his leadership in giving the U.S. Food and Drug Administration (FDA) the authority to regulate e-cigarettes and other currently unregulated tobacco products. The 2009 Family Smoking Prevention and Tobacco Control ...
ASCO Launches Electronic Practical Tips for the Oncology Practice, 6th Edition
In mid-May, ASCO launched Practical Tips for the Oncology Practice, 6th Edition, a comprehensive resource providing answers to the most commonly asked questions regarding billing, coding, reimbursements, coverage questions, and regulatory policies that affect the day-to-day practice of oncology....
New ASCO Journal to Focus on Cancer in Resource-Constrained Countries
Internationally renowned oncologist David Kerr, MD, DSc, will serve as founding Editor-in-Chief of the new ASCO publication, Journal of Global Oncology (JGO). JGO will be the first journal focused exclusively on cancer research, treatment, and care delivery in middle- and low-resource countries...
Institute of Medicine to Become National Academy of Medicine
At its 152nd Annual Meeting on April 28, 2015, the membership of the National Academy of Sciences voted to change the name of the Institute of Medicine to the National Academy of Medicine. The newly named National Academy of Medicine will continue to be an honorific society and will inherit the...
Large Urology Group Practice Association Appoints President-Elect
Neal Shore, MD, FACS, of Atlantic Urology Clinics, LLC, was recently appointed President-Elect of the Large Urology Group Practice Association (LUGPA). “I am honored to be appointed to this prestigious position within [the Association] and look forward to furthering the organization’s goal,...
Eduardo M. Sotomayor, MD, Named Director of GW Cancer Center
The George Washington University (GW) School of Medicine and Health Sciences (SMHS), the GW University Hospital, and the GW Medical Faculty Associates announced the appointment of Eduardo M. Sotomayor, MD, as the inaugural Director of the GW Cancer Center (GWCC). He will also serve as a Professor...
The Basket Trial: An Evolving Clinical Trial Design
The recently published results of the CUSTOM (Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies) trial, reviewed in this issue of The ASCO Post, describe a basket trial focused on identifying molecular biomarkers in advanced non–small cell lung cancer (NSCLC), small...
What Is the Future of Intraperitoneal Treatment in Advanced Ovarian Cancer?
An analysis of Gynecologic Oncology Group (GOG) studies recently reported in the Journal of Clinical Oncology by Tewari and colleagues and reviewed in this issue of The ASCO Post showed a survival benefit of intraperitoneal chemotherapy vs intravenous chemotherapy over long-term follow-up in women...
Studies Evaluate Effectiveness of Active Surveillance in Prostate Cancer Patients
Active surveillance has become a viable option for many men with low-risk prostate cancer who choose not to undergo active treatment such as surgery or radiotherapy. Four studies evaluating the effectiveness, trends, and other considerations for active surveillance in managing prostate cancer were...
New Studies Call for Smarter Approach to Prostate Cancer Screening
Prostate cancer is one of the most common cancers in American men, yet controversy over the utilization and frequency of prostate-specific antigen (PSA) screening methods remains, due to the overdiagnosis and overtreatment of men with low-grade, less-aggressive forms of the disease. At the 110th...
Intensified Therapy Improves Survival in Wilms Tumor Patients With Rare Genetic Abnormality
Data from two phase III studies led by the Children’s Oncology Group show that augmenting or intensifying therapy for children with high-risk Wilms tumor improved relapse-free survival. These children are deemed to be at high risk due to a specific chromosomal abnormality that confers worse...
Whole-Brain Radiation: Risks Outweigh Benefits for Limited Brain Metastases
New data from a phase III Alliance trial weighs in on a longstanding debate in the treatment of brain metastases: Should whole-brain radiation therapy be added to stereotactic radiosurgery? The study found that although whole-brain radiation therapy improved local tumor control in patients with...
Clinically Meaningful Preliminary Results With Pembrolizumab in Recurrent Head and Neck Cancer
Pembrolizumab (Keytruda) is making inroads into head and neck cancer, with encouraging results in heavily pre-treated patients with recurrent or metastatic squamous cell carcinoma of the head and neck, according to a report on the expansion-cohort KEYNOTE-012 study presented at the 2015 ASCO...
Second-Line Nivolumab Therapy Improves Survival in Patients With Nonsquamous Non–Small Cell Lung Cancer
Anti–programmed cell death protein 1 (PD-1) immunotherapy with nivolumab (Opdivo) extended survival in patients with the most common form of lung cancer—nonsquamous non–small cell lung cancer (NSCLC). Patients whose disease progressed on standard platinum doublet therapy who were treated with...
Expert Point of View: Neil Howard Segal, MD, PhD
Neil Howard Segal, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, who discussed the study at the 2015 ASCO Annual Meeting, emphasized that pembrolizumab (Keytruda) exerted a “clear benefit in patients with mismatch repair deficiency,” based on the “very impressive response rate of...
